

**BY REG. A.D.****hand delivery**

971

NO.VAD/324694/NSQ/
Office of the Joint Commissioner/Assistant Commissioner,
Food & Drugs Control Administration
C/O Food & Drugs laboratory,
Nr. PolyTechnic,
Vadodara
Date:03/02/2026

To,

CENTRAL MEDICAL STORES
E.S.I.S
GOTRI ROAD
VADODARA

10 6 FEB 2026

Sub.: Drugs & Comestics Act, 1940 & Rules thereunder.

Ref.: Form No. 17 Dated 23/02/2025
NIF-20 SR TAB
Batch no. NR011
Mfged. By NABROS PHARMA PVT LTD

Sir,

I, have to state that sample of **NIF-20 SR TAB** Batch no. **NR011** Mfged. By **NABROS PHARMA PVT LTD**, N.H.No.8, **KHEDA**, **KHEDA** was picked up from your premises for test and analysis. The Government Analyst. has reported the sample in question to be of **NOT OF STANDARD QUALITY** vide his Test Report No. **q1-734-26 Dt. 02/02/2026** (Test Rpt No : **NSQ/BDL/324694/2026**)

Original Test Report is enclosed herewith.

1. You are therefore asked to **STOP SALE / DISTRIBUTION** of the product & recall all the stock of the subject drug sold / distributed immediately.
2. You are asked to return this product to the supplier under intimation to this Office.
3. As per Section 18A , 22(1) (cca) of said Act you are hereby required to furnish the information along with certified photo copies of document vide which you have acquired / distributed / sold the said drugs within 3 days of the receipt of this letter.

Remarks: The sample does not conforms to the standards laid down for Nifedipine sustained-release Tablets in IP 2022 with respect to Dissolution (in Acid Stage).

Reasons: Dissolution

Yours Faithfully

Food & Drugs Control Administration
Vadodara

No. FDL/AR/ 821 /2026
 Food & Drugs Laboratory, Vadodara.
 Dated:..... 2026

From :
 THE GOVERNMENT ANALYST,
 Food & Drugs Laboratory,
 Vadodara-390 002.

2 FEB 2026

To,
 N. M. Malani,
 Drugs Inspector,
 C/O Food & Drugs laboratory,
 Nr. Poly Technic, Vadodara,
 Vadodara.

Report No. : Q-1/ /2026 (ESIS)

734 - 7

FORM - 13
 (See Rule 46)

**Certificate of test or analysis by Government Analyst under
 Section 25 (1) of the Drugs and Cosmetic Act, 1940**

1. Name of Inspector from whom received : N. M. Malani,
2. Serial No. and date of Inspector's Memorandum. : VAD/Regular/Emp. State Insurance/ 324694/GJ-BDL Date :- 29/03/2025
3. Number of Sample : 1 x 5 x 10 Tablets
4. Date of receipt : 05/04/2025
5. Name of drugs purporting to be contained in the sample:- NIF-20 SR TAB.,
 Manufactured in India by:- Nabrose Pharma Pvt Ltd. N. H. No 8 Kheda 387411 India.
6. Condition of seals on the packet or on portion of samples or container:- Seals were intact & identical With the specimen impression of the seal received separately from Drugs Inspector.
7. Results of test or analysis with protocols of test or analysis applied:- Is attached.
 In the opinion of the Undersigned the sample referred above.

~~Is of standard quality as defined in the Drugs and Cosmetics Act, 1940 and Rules there under~~

Is not of standard quality as defined in the Drugs and Cosmetics Act, 1940 and Rules there under for the reasons given below:-

The sample **does not** conforms to the standard laid down for "Nifedipine sustained-release Tablets" in IP 2022 with respect to Dissolution (In acid stage)

Date :
 Hetal

2 FEB 2026



(Mr. P. J. Parmar)
 Government Analyst,
 Page No. I of II.

734

"Test Report"

REPORT NO. : Q-1/

/2026 (ESIS)

SAMPLE NO. : 33/25

"NIF-20 SR TAB"**Results of the tests or analysis with protocols of test or analysis applied:-**

Outer label : NIL
Container label : Nifedipine Sustained Release Tablets IP 20 mg
 NIF-20 SR
 Composition
 Each film coated sustained release tablet contains-
 Nifedipine IP 20 mg
 Color : Sunset yellow FCF
 Excipients q.s.
 Store in a cool & dry place.
 ESI supply not for sale
 Mfg. Lic. No.:- G/1355 B. No. :- NR011
 Mfg. Date.:- 10/2024 Exp. Date.:- 09/2027
 Manufactured in India by:- Nabrose Pharma Pvt Ltd.
 N. H. No 8 Kheda 387411 India.

For the following tests and assay methods given in I.P. 2022 under "Nifedipine Extended-release Tablets" Page No. 3064 are followed.

Description : Orange colored circular, biconvex coated tablet.
Content : 10 Tablets per strip. (05 strip)
Identification : Complies with the test for Identification.
Average weight of tablet : 0.1019 gm
Dissolution : **Not Within IP 2022 Limits.**
 (In acid stage tablet not release between 25 to 45 percent)

Assayed for Nifedipine Content:-

Nifedipine : 19.32 mg per average weight of tablet.
 (C₁₇H₁₈N₂O₆) (i.e. 96.60 percent of the claim made)

[I.P. 2022 Limits:- Nifedipine Prolonged-release Tablets contains not less than 90.0 percent and not more than 110.0 percent of the stated amount of Nifedipine, C₁₇H₁₈N₂O₆]

Date of Date of performance: From 02/07/25 to
 Checked by: ASR



(Mr. P. J. Parmar)
 Government Analyst
 Page No. II of II

..... **End of the report.**

Disclaimer: This report refers only to a particular sample submitted for testing, Laboratory is not involved in sampling, **Address:** Food & Drugs Laboratory, Near Polytechnic, Nizampura-390002, Vadodara.